Merck and Co. reported higher-than-expected second quarter earnings after more people started using two of its diabetes medications, said Bloomberg.
The company expected a downturn in profits because its asthma medicine is now facing generic competition.
Revenue climbed 1.3 percent to $12.3 billion.
Read more at Bloomberg.